Cardio3 BioSciences acquires CorQuest Medical Inc.

5 November 2014- Mont saint Guibert, Belgium
The belgian biotech Cardio3 BioSciences, leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today that it has acquired U.S.-based CorQuest Medical Inc.

CorQuest Medical, based in Miami, but incorporated in Delaware in July 2012, specializes in the development of innovative devices and technologies for cardiac surgery. It was founded by a Belgian,  Dr. Didier De Cannière.

Euronext Brussels and Paris: CARD

Featured company : ILLUMINA, San Diego, California

20 October 2014 - illumina, Inc. based in Sand Diego, California, is an American company incorporated in April 1998 that develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function (DNA sequencing, Genome sequencing).
NASDAQ:  Illumina

GSK develops Ebola vaccine

19 October 2014- GSK says Ebola vaccine development progressing at 'unprecedented rate'

GlaxoSmithKline is working to develop a vaccine to combat Ebola, which has killed thousands in West Africa, was moving at a rapid pace.

"Development of the vaccine candidate is progressing at an unprecedented rate, with first phase 1 safety trials with the vaccine candidate underway in the USA, UK and Mali, and further trials due to start in the coming weeks," the firm said in a statement posted on its website.
Source : REUTERS

GSK on London Stock exhange : GSK

Ebola - Facebook founder Mark Zuckerberg And Wife Priscilla Chan Donate $25 Million To Fight Ebola

14 October 2014 - Facebook founder Mark Zuckerberg and his wife Priscilla Chan announced on Tuesday that they are donating $25 million to the Centers for Disease Control Foundation (CDC)  to fight Ebola.
Zuckerberg revealed the donation in a post on Facebook. In a status update, Zuckerberg compared the disease to Polio and HIV, noting that 8,400 people have already been infected by Ebola and that it has the potential to spread quickly.
 
Billionaire Bill Gates announced last month that

L'INAMI publie son rapport annuel 2013

Brussels - 13 octobre 2014 

L' INAMI - l'nstitut national d'assurance maladie-invalidité (Belgique) vient de publier son rapport annuel 2013. Le rapport complet est disponible sur le site de l'INAMI (www.inami.fgov.be). Il fournit également un aperçu détaillé des statistiques de l'assurance maladie-invalidité.

Ce rapport trace le portrait de l’assurance soins de santé et indemnités en Belgique. On y apprend notamment que :

• Le Belge a coûté en moyenne 2256,04 euros à l'assurance soins de santé en 2012, soit 3,18% de plus qu'en 2011 et 7,80% de plus qu'en 2010, ressort-il du rapport 2012 de l'Inami publié lundi. Le nombre de personnes invalides a quant à lui continué à augmenter en 2013.

• A la fin décembre 2013, 320 823 personnes (salariés et indépendants) percevaient des indemnités d'invalidité en Belgique, soit 4,5% de la population entre 15 et 64 ans. Cela représente une augmentation de 5,37% par rapport à 2012. La première cause d'invalidité reste les troubles mentaux (109 000 personnes fin 2013, ou 38,4% des personnes en invalidité). Le nombre d'invalides pour cette raison a grimpé de près de 58% en dix ans et de 88% depuis 2000, souligne le rapport.

La santé mentale représente

Valby, DK - 05-05-2014 - Lundbeck receives grant from The Michael J. Fox Foundation for biological markers identification in Parkinson’s disease

A Lundbeck research program aiming to increase the knowledge of how a specific change in a gene (Lrrk2) contributes to an increased risk of developing Parkinson's disease was granted DKK 3,5m from The Michael J. Fox Foundation, the world's largest nonprofit funder of Parkinson's disease research.

Medical device maker Sequana raises $26m after quitting US

28 April 2014 - Sequana Medical  raises $26m after relocating from California to Zug in Switerland.
Sequana raised the investment in a financing round led by Life Sciences Partners, a European private equity fund (Germany, The Netherlands).
Source :
- Financial Times
http://www.ft.com/cms/s/0/afbd51e8-cc79-11e3-bd33-00144feabdc0.html#axzz30DLBh8zz
- Sequana news


About Life Sciences Partners
In April 2011, LSP launched its LSP Life Sciences Fund on Euronext. This fund is open-ended and publicly listed. As such, it allows investors to buy shares of the fund at any time, via their (internet) broker. The fund’s Bloomberg ticker is LSP NA and its ISIN Code is NL0009756394.

Novadip Biosciences

BRUSSELS (Reuters) - January 2014 - Belgian medical researchers have succeeded in repairing bones using stem cells from fatty tissue, with a new technique they believe could become a benchmark for treating a range of bone disorders.
The team at the Saint Luc university clinic hospital in Brussels have treated 11 patients, eight of them children, with fractures or bone defects that their bodies could not repair, and a spin-off is seeking investors to commercialize the discovery.